Кристи Фанк - Грудь. Руководство пользователя [litres]

E. Styring et al., “Radiation-Associated Angiosarcoma after Breast Cancer: Improved Survival by Excision of All Irradiated Skin and Soft Tissue of the Thoracic Wall? A Report of Six Patients,” Acta Oncologica 54, no. 7 (2015): 1078–1080.

T. Grantzau and J. Overgaard, “Risk of Second Non-Breast Cancer among Patients Treated with and without Postoperative Radiotherapy for Primary Breast Cancer: A Systematic Review and Meta-analysis of Population-Based Studies including 522,739 Patients,” Radiotherapy and Oncology 121, no. 3 (2016): 402–413.

C. Shah et al., “Brachytherapy-Based Partial Breast Irradiation Is Associated with Low Rates of Complications and Excellent Cosmesis,” Brachytherapy 12, no. 4 (2013): 278–284.

National Comprehensive Cancer Network (NCCN), “NCCN Clinical Practice Guidelines in Oncology: Breast Cancer,” https://www.nccn.org/professionals/physician_gls/default.aspx.

I. H. Kunkler et al., “Breast-Conserving Surgery with or Without Irradiation in Women Aged 65 Years or Older with Early Breast Cancer (PRIME II): A Randomised Controlled Trial,” The Lancet Oncology 16, no. 3 (2015): 266–273.

B. McCormick et al., “RTOG 9804: A Prospective Randomized Trial for Good-Risk Ductal Carcinoma In Situ Comparing Radiotherapy with Observation,” Journal of Clinical Oncology 33, no. 7 (March 2015): 709–715.

M. Donker et al., “Breast-Conserving Treatment with or Without Radiotherapy in Ductal Carcinoma In Situ: 15-Year Recurrence Rates and Outcome after a Recurrence, from the EORTC 10853 Randomized Phase III Trial,” Journal of Clinical Oncology 31, no. 32 (2013): 4054–4059.

L. J. Solin et al., “A Multi-Gene Expression Assay to Predict Local Recurrence Risk for Ductal Carcinoma In Situ of the Breast,” Journal of the National Cancer Institute 105, no. 10 (May 2013): 701–710.

C. E. DeSantis et al., “Breast Cancer Statistics, 2015: Convergence of Incidence Rates Between Black and White Women,” CA: A Cancer Journal for Clinicians 66, no. 1 (2016): 31–42.

J. F. R. Robertson et al., “Fulvestrant 500 mg versus Anastrozole 1 mg for Hormone Receptor-Positive Advanced Breast Cancer (FALCON): An International, Randomised, Double-Blind, Phase 3 Trial,” The Lancet 388, no. 10063 (2016): 2997–3005.

Early Breast Cancer Trialists’ Collaborative Group, “Relevance of Breast Cancer Hormone Receptors and Other Factors to the Efficacy of Adjuvant Tamoxifen: Patient-Level Meta-analysis of Randomised Trials,” The Lancet 378, no. 9793 (2011): 771–784.

A. Howell et al., “Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) Trial after Completion of 5 Years’ Adjuvant Treatment for Breast Cancer,” The Lancet 365, no. 9453 (2005): 60–62.

O. Pagani, M. M. Regan, and P. A. Francis, “TEXT and SOFT Investigators; International Breast Cancer Study Group. Exemestane with Ovarian Suppression in Premenopausal Breast Cancer,” New England Journal of Medicine 371 (2014): 1358–1359.

C. Davies et al., “Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) Collaborative Group. Long-Term Effects of Continuing Adjuvant Tamoxifen to 10 Years versus Stopping at 5 Years after Diagnosis of Oestrogen Receptor-Positive Breast Cancer: ATLAS, a Randomised Trial,” The Lancet 381 (2013): 805–816.

P. E. Goss et al., “A Randomized Trial of Letrozole in Postmenopausal Women after Five Years of Tamoxifen Therapy for Early-Stage Breast Cancer,” New England Journal of Medicine 349 (2003): 1793–1802.

D. C. Allred et al., “Adjuvant Tamoxifen Reduces Subsequent Breast Cancer in Women with Estrogen Receptor-Positive Ductal Carcinoma In Situ: A Study Based on NSABP Protocol B-24,” Journal of Clinical Oncology 30, no. 12 (April 2012): 1268–1273.

L. Fallowfield et al., “Quality of Life of Postmenopausal Women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Adjuvant Breast Cancer Trial,” Journal of Clinical Oncology 22, no. 21 (November 2004): 4261–4271.

D. Slamon et al., “Adjuvant Trastuzumab in HER2-Positive Breast Cancer,” New England Journal of Medicine 365 (2011): 1273–1283.

H. S. Rugo et al., “Heritage: A Phase III Safety and Efficacy Trial of the Proposed Trastuzumab Biosimilar Myl-1401O versus Herceptin,” Journal of Clinical Oncology 34, no. 18, LBA503.

R. S. Finn et al., “The Cyclin-Dependent Kinase 4/6 Inhibitor Palbociclib in Combination with Letrozole versus Letrozole Alone as First-Line Treatment of Oestrogen Receptor-Positive, HER2-Negative, Advanced Breast Cancer (PALOMA-1/TRIO 18): A Randomised Phase 2 Study,” The Lancet Oncology 16, no. 1 (2015): 25–35; “Ribociclib Effective in Younger Breast Cancer Patients Too,” Medscape, December 8, 2017, https://www.medscape.com/viewarticle/889777?nlid=119488_2202.

H. L. McArthur and D. B. Page, “Immunotherapy for the Treatment of Breast Cancer: Checkpoint Blockade, Cancer Vaccines, and Future Directions in Combination Immunotherapy,” Clinical Advances in Hematology and Oncology 14, no. 11 (2016): 922–933.

E. M. Walker et al., “Acupuncture versus Venlafaxine for the Management of Vasomotor Symptoms in Patients with Hormone Receptor-Positive Breast Cancer: A Randomized Controlled Trial,” Journal of Clinical Oncology 28, no. 4 (2009): 634–640.

T. Gansler et al., “A Population‐Based Study of Prevalence of Complementary Methods Use by Cancer Survivors,” Cancer 113, no. 5 (2008): 1048–1057.

M. A. Richardson et al., “Complementary/Alternative Medicine Use in a Comprehensive Cancer Center and the Implications for Oncology,” Journal of Clinical Oncology 18, no. 13 (2000): 2505–2514.

H. S. Boon, F. Olatunde, and S. M. Zick, “Trends in Complementary/Alternative Medicine Use by Breast Cancer Survivors: Comparing Survey Data from 1998 and 2005,” BMC Women’s Health 7, no. 1 (2007): 4.

A. Molassiotis et al., “Use of Complementary and Alternative Medicine in Cancer Patients: A European Survey,” Annals of Oncology 16, no. 4 (2005): 655–663. Глава десятая. И что теперь? Жизнь после постановки диагноза и лечения

J. L. Khatcheressian et al., “Breast Cancer Follow-Up and Management after Primary Treatment: American Society of Clinical Oncology Clinical Practice Guideline Update,” Journal of Clinical Oncology 31, no. 7 (2012): 961–965.

The GIVIO Investigators, “Impact of Follow-Up Testing on Survival and HealthRelated Quality of Life in Breast Cancer Patients. A Multicenter Randomized Controlled Trial,” Journal of the American Medical Association 271, no. 20 (May 1994): 1587–1592; S. De Placido et al., “Imaging Tests in Staging and Surveillance of Non-metastatic Breast Cancer: Changes in Routine Clinical Practice and Cost Implications,” British Journal of Cancer 116, no. 6 (2017): 821.